Physician profile
Monika Mannan
NPI 1558472498
$8,229.40
in general payments reported to CMS, 2019-2025
41 companies · $2,573 in 2025
The $2,573 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $460 · 2021: $482 · 2022: $941 · 2023: $1,297 · 2024: $1,482 · 2025: $2,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,646 · Travel and Lodging: $657 · Education: $48.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,646.40 |
| Travel and Lodging | $657.33 |
| Education | $48.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,156.04 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Medtronic, INC. | $997.62 | 2023-2025 | Minimed 780g, Minimed 770g, Mycarelink |
| Lilly USA, LLC | $828.16 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $621.20 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Corcept Therapeutics | $584.92 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $458.90 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $450.32 | 2019-2022 | |
| Abbvie INC. | $300.85 | 2022-2024 | |
| Insulet Corporation | $262.72 | 2019-2025 | Omnipod, Omnipod |
| Madrigal Pharmaceuticals | $218.14 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $196.86 | 2021-2025 | Unithroid |
| Mannkind Corporation | $194.47 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $164.93 | 2023-2025 | |
| Echosens North America, INC. | $159.60 | 2023 | Fibroscan |
| Xeris Pharmaceuticals, INC. | $152.65 | 2021-2024 | Recorlev, Gvoke Hypopen |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $149.41 | 2019-2023 | Tepezza |
| Alexion Pharmaceuticals, INC. | $131.12 | 2024 | |
| Glaxosmithkline, LLC. | $125.01 | 2025 | Arexvy |
| Tandem Diabetes Care, INC. | $120.26 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $105.61 | 2020-2023 | Evenity, Prolia |
| Medtronic Minimed, INC. | $105.28 | 2019-2020 | |
| Beta Bionics, INC. | $101.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Esperion Therapeutics, INC. | $75.39 | 2021-2025 | Nexletol |
| Recordati_rare_diseases_inc. | $60.93 | 2024-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $59.42 | 2020-2022 | |
| Pfizer INC. | $56.35 | 2023 | |
| Sequel Med Tech, LLC | $52.55 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.32 | 2024-2025 | Jardiance |
| Acella Pharmaceuticals, LLC | $41.60 | 2025 | NP Thyroid 60 |
| Abbott Laboratories | $29.15 | 2021-2023 | Freestyle Libre 3 |
| Alfasigma USA, INC. | $24.94 | 2021 | |
| Soleno Therapeutics, INC. | $24.10 | 2025 | Vykat Xr |
| Chiesi USA, INC. | $23.58 | 2024 | Myalept |
| Ascendis Pharma Endocrinology INC | $23.56 | 2025 | Yorvipath |
| Antares Pharma, INC. | $23.44 | 2023 | Tlando, Xyosted, Nocdurna |
| Nevro Corp. | $22.83 | 2024 | Senza |
| Shire North American Group INC | $17.94 | 2019 | |
| Lifescan, INC. | $16.74 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.71 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.87 | 2023 | Cycloset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Mannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.